Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068364 | 0.91 | LTB4R2 (0.43) | LTB4R2ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL7098737 | 0.89 | LMNA (0.40) | ALDH1A1AGTR1EDNRAMMP3MAPT | |
| SCHEMBL7087252 | 0.88 | TP53 (0.36) | AGTR1TSHREDNRAMAPTLMNA | |
| SCHEMBL7072131 | 0.83 | LTB4R2 (0.43) | LTB4R2ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL6752250 | 0.82 | MAPT (0.39) | ALDH1A1AGTR1EDNRBEDNRAMMP3 | |
| SCHEMBL7069951 | 0.81 | F10 (0.50) | — | |
| SCHEMBL7072269 | 0.80 | F10 (0.42) | LTB4R2ALDH1A1TSHRMAPT | |
| SCHEMBL7096610 | 0.80 | PDE4A (0.42) | ALDH1A1AGTR1EDNRBEDNRAMAPT | |
| SCHEMBL7072311 | 0.80 | L3MBTL1 (0.43) | ALDH1A1TSHRMAPTLMNAHPGD | |
| SCHEMBL7089977 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | MERCK-PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | F12, F11, PLAT | LTB4R2 690/4885ALDH1A1 871/4885AGTR1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.